Act before FDA deadline on October 13
The US Department of Health and Human Services (HHS) declared Monkeypox a public health emergency on August 9, 2022 , allowing the US FDA to grant Emergency Use Authorization (EUA) to IVD manufacturers developing monkeypox virus tests. FDA has issued an EUA guidance for monkeypox and is prioritizing the review of applications from experienced manufacturers with high manufacturing capacity who are developing:
TE’s IVD Solutions Team has helped numerous COVID-19 test manufacturers meet FDA EUA requirements and our clinical and regulatory teams are ready to assist you in obtaining monkeypox EUA as quickly as possible. Time is of the essence as you must notify FDA of your intent to file an EUA no later than October 13, 2022.
Proven Expertise, From Concept to Market
A key FDA requirement for granting a monkeypox Emergency Use Authorization is the requirement to conduct a clinical study with at least 30 positive and 30 negative samples from patients suspected of carrying the monkeypox virus. Antigen test developers must use actual clinical samples for this testing. With more than 125 clinical sites around the United States, TE can quickly execute a clinical study of your assay and demonstrate compliance with FDA sensitivity, specificity, and reactivity requirements for monkeypox tests. Our IVD Solutions team can: